NewAmsterdam reports positive Phase 3 BROOKLYN data; Q2 net loss $39M

NewAmsterdam Pharma Co N.V.

2024-Q2 EPS reported -$1.45 revenue$3,680,000

Phase 3 BROOKLYN met primary endpoint: LS mean LDL-C reduction 36.3% at day 84 (p<0.0001), sustained at day 365 (-41.5%); safety comparable to placebo.
US composition of matter patent issued for obicetrapib, extending IP protection to July 2043.
Cash $430.7M as of June 30, 2024 (up from $340.5M at Dec 31, 2023).
Q2 net loss $39.0M ($0.41 diluted EPS) vs $38.3M ($0.47) year ago; revenue $2.3M (vs $1.7M).
Topline data for Phase 3 BROADWAY expected Q4 2024; Phase 3 TANDEM enrollment completed, topline Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.